The current financial score of Perspective Therapeutics Inc is 5.75. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 81.00K, representing a year-over-year decrease of 72.07%, while its net profit experienced a year-over-year decrease of 24.67%.
The current valuation score of Perspective Therapeutics Inc is 6.97. Its current P/E ratio is -1.79, which is -23.23% below the recent high of -1.37 and -629.59% above the recent low of -13.04.
The current earnings forecast score of Perspective Therapeutics Inc is 8.14. The average price target is 12.29, with a high of 18.00 and a low of 5.00.
The current price momentum score of Perspective Therapeutics Inc is 4.48. Currently, the stock price is trading between the resistance level at 3.01 and the support level at 2.22, making it suitable for range-bound swing trading.
The current institutional shareholding score of Perspective Therapeutics Inc is 5.00. The latest institutional shareholding proportion is 54.19%, representing a quarter-over-quarter decrease of 34.77%. The largest institutional shareholder is James Simons, holding a total of 59.13K shares, representing 0.00% of shares outstanding, with 47.25% decrease in holdings.
The current risk assessment score of Perspective Therapeutics Inc is 3.83. The company's beta value is 1.74. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.